The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Abstract
CONTEXT: Alzheimer disease (AD) and Parkinson disease (PD) are associated with neuronal degeneration in major subcortical nuclei, but few studies have examined the neuronal degeneration in these nuclei concurrently. OBJECTIVE: To identify clinical and pathological correlates of neuronal loss in the nucleus basalis (NB), locus coeruleus (LC), and substantia nigra pars compacta (SN) in AD and PD. DESIGN: The study sample comprised 86 cases with pathologically confirmed AD, 19 cases with PD, and 13 healthy elderly control subjects. The number of nucleolated neurons was counted in representative sections of the NB, LC, and SN. Effect sizes (ES) were computed to determine the standardized difference in cell counts relative to healthy controls. RESULTS: Cases of AD showed the greatest neuronal loss in the LC (ES = 3.16) followed by the NB (ES = 1.10), but variable loss in the SN (ES = 0.16). Cases of PD also showed the greatest neuronal loss in the LC (ES = 6.47), followed by the SN (ES = 2.58) and the NB (ES = 0.85). Significant correlations were found between the number of neurons in the NB and LC in PD (r = 0.54, P<.05), as well as AD (r = 0.24, P<.05). The duration of illness correlated with greater neuronal loss in the LC and NB in AD, and greater neuronal loss in the SN in PD. CONCLUSIONS: For both AD and PD the greatest neuronal loss was found in the LC. In AD, neuronal loss was most severe and best correlated with the duration of illness in the LC, rather than in NB as traditionally expected. Correlations between neuronal loss in the LC and NB (but not SN) in both PD and AD suggest that the former 2 nuclei may share common pathogenetic susceptibilities. Given the prominent loss of neurons in the LC, detection and treatment of noradrenergic deficiencies warrant attention in both AD and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Senile dementia of Lewy body type
Perry, R. H., Irving, D., Blessed, G., Fairbairn, A., & Perry, E. K. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90236-g · Cited by 571
Perry, E. K., Curtis, M., Dick, D. J., Candy, J. M., Atack, J. R., Bloxham, C. A., Blessed, G., Fairbairn, A., Tomlinson, B. E., & Perry, R. H. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.413 · Cited by 571
Disease‐specific patterns of locus coeruleus cell loss
German, D. C., Manaye, K. F., White, C. L., Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., & Mann, D. M. A. (1992) · Annals of Neurology · doi:10.1002/ana.410320510 · Cited by 512
Chan‐Palay, V., & Asan, E. (1989) · Journal of Comparative Neurology · doi:10.1002/cne.902870308 · Cited by 495
DSTAT : software for the meta-analytic review of research literatures
Johnson, B. T. (1989) · Medical Entomology and Zoology · Cited by 489
Piggott, M. A., Marshall, E. F., Thomas, N., Lloyd, S., Court, J. A., Jaros, E., Burn, D., Johnson, M., Perry, R. H., McKeith, I. G., et al. (1999) · Brain · doi:10.1093/brain/122.8.1449 · Cited by 330
Arendt, T., Schindler, C., Brückner, M. K., Eschrich, K., Bigl, V., Zedlick, D., & Marcova, L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00516.1997 · Cited by 319
Cited by
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future
Plog, B. A., & Nedergaard, M. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-051217-111018 · Cited by 780
Olfactory dysfunction in Parkinson disease
Doty, R. L. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.80 · Cited by 737
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
Cognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013) · Neurodegenerative Diseases · doi:10.1159/000341998 · Cited by 573
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology · doi:10.1002/ana.20186 · Cited by 548
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524
“, celiac ganglia and ENS, of PD patients [18,19,20,21].”
BackgroundAlexander, G. E. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/galexander · Cited by 523
Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jardanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U.-K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909586107 · Cited by 518
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain
Mather, M., & Harley, C. W. (2016) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.01.001 · Cited by 492
Revisiting the cholinergic hypothesis in the development of Alzheimer's disease
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 486
Grisold, W., Cavaletti, G., & Windebank, A. J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos203 · Cited by 486
The Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?
Mesulam, M. (2004) · Learning & Memory · doi:10.1101/lm.69204 · Cited by 467
Samuels, E., & Szabadi, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777193 · Cited by 454
Snakes as agents of evolutionary change in primate brains
Isbell, L. A. (2006) · Journal of Human Evolution · doi:10.1016/j.jhevol.2005.12.012 · Cited by 451
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“Interestingly, LC loss correlates better with the clinical course of the disease and the severity of dementia than loss of the nucleus basalis of Meynert and perturbation of the cholinergic system (Zarow et al. 2003).”
BackgroundArgyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008) · Blood · doi:10.1182/blood-2008-04-149385 · Cited by 432
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 431
Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P., Rodriguez, R. D., Mejia, M. B., Suemoto, C. K., Ferretti-Rebustini, R. E. D. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2362 · Cited by 416
Noradrenergic mechanisms in neurodegenerative diseases: a theory
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.002 · Cited by 414
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases
Chi, H., Chang, H.-Y., & Sang, T.-K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103082 · Cited by 412
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396
Ma, K., Xiong, N., Shen, Y., Han, C., Liu, L., Zhang, G., Wang, L., Guo, S., Guo, X., Xia, Y., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00001 · Cited by 379
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Liu, A. K. L., Chang, R. C.-C., Pearce, R. K. B., & Gentleman, S. M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1392-5 · Cited by 368
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0825-z · Cited by 359
Loss of locus coeruleus neurons and reduced startle in parkin null mice
von Coelln, R., Thomas, B., Savitt, J. M., Lim, K. L., Sasaki, M., Hess, E. J., Dawson, V. L., & Dawson, T. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401297101 · Cited by 347
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
Functional neuroanatomy of the central noradrenergic system
Szabadi, E. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113490326 · Cited by 335
Absolute requirement of GDNF for adult catecholaminergic neuron survival
Pascual, A., Hidalgo-Figueroa, M., Piruat, J. I., Pintado, C. O., Gómez-Díaz, R., & López-Barneo, J. (2008) · Nature Neuroscience · doi:10.1038/nn.2136 · Cited by 334
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
SLC6 transporters: Structure, function, regulation, disease association and therapeutics
Pramod, A. B., Foster, J., Carvelli, L., & Henry, L. K. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.002 · Cited by 319
Benarroch, E. E. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c2937c · Cited by 317
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25095 · Cited by 315
Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305
Diederich, N. J., Goetz, C. G., & Stebbins, G. T. (2005) · Movement Disorders · doi:10.1002/mds.20308 · Cited by 290
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286
“While morphometric studies of LC cell loss help to delineate its relative status within the spatiotemporal pattern of selective neuronal vulnerability in AD [7, 108, 124], the molecular mechanisms underlying LC neurodegeneration during disease progression have yet to be fully understood.”
Pathophysiology of somatosensory abnormalities in Parkinson disease
Conte, A., Khan, N., Defazio, G., Rothwell, J. C., & Berardelli, A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.224 · Cited by 280
Progression of motor impairment and disability in Parkinson disease: A population-based study
Alves, G., Wentzel-Larsen, T., Aarsland, D., & Larsen, J. P. (2005) · Neurology · doi:10.1212/01.wnl.0000183359.50822.f2 · Cited by 271
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Cenci, M. A., & Lundblad, M. (2007) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0925s41 · Cited by 266
Parkinsonian signs and substantia nigra neuron density in decendents elders without PD
Ross, G. W., Petrovitch, H., Abbott, R. D., Nelson, J., Markesbery, W., Davis, D., Hardman, J., Launer, L., Masaki, K., Tanner, C. M., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20226 · Cited by 260
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Vascular Degeneration in Parkinson's Disease
Guan, J., Pavlovic, D., Dalkie, N., Waldvogel, H. J., O'Carroll, S. J., Green, C. R., & Nicholson, L. F. B. (2013) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00628.x · Cited by 191
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25187 · Cited by 184
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159
Principles of Neuroplasticity-Based Rehabilitation
Nahum, M., Lee, H., & Merzenich, M. M. (2013) · Progress in Brain Research · doi:10.1016/b978-0-444-63327-9.00009-6 · Cited by 158
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153
“In contrast, age was significantly related to avb3 density in the locus ceruleus, a region reported to have significant neuronal loss in AD (Zarow et al. 2003).”
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
“These results are in line with several postmortem studies, which have shown that in advanced PD cases, the cell loss in non-dopaminergic nuclei ranges between 30 and 50%, whereas it is close to 80% in the nigral region (Jellinger, 1991; Zarow et al., 2003; Thannickal et al., 2007).”
ResultChalermpalanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C., Lah, J. J., Levey, A. I., & Weinshenker, D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1483-17.2017 · Cited by 136
“Extensive LC degeneration is nearly universal in AD (Bondareff et al., 1987; Chan-Palay and Asan, 1989; Lyness et al., 2003; Zarow et al., 2003; Haglund et al., 2006) and is among the earliest pathologies (Forno, 1966; Mann et al.”
BackgroundHuang, X., Abbott, R. D., Petrovitch, H., Mailman, R. B., & Ross, G. W. (2008) · Movement Disorders · doi:10.1002/mds.22013 · Cited by 124
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease
Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., & Feinstein, D. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.012 · Cited by 116
“, 1987) and duration of illness (Zarow et al., 2003).”
BackgroundGoldstein, D. S. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00396.2018 · Cited by 96
Colombo, G., Cubero, R. J. A., Kanari, L., Venturino, A., Schulz, R., Scolamiero, M., Agerberg, J., Mathys, H., Tsai, L.-H., Chachólski, W., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01167-6 · Cited by 100
Ossowska, K., Śmiałowska, M., Kuter, K., Wierońska, J., Zięba, B., Wardas, J., Nowak, P., Dąbrowska, J., Bortel, A., Biedka, I., et al. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.039 · Cited by 84
Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease
Fifel, K., & Cooper, H. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.024 · Cited by 80
“Results from a number of studies support the involvement of dysfunctional homeostatic processes as an underlying feature of sleep disturbances in PD (Forno et al., 1993; Fronczek et al., 2007; Fulceri et al., 2007; Hirsch et al., 1987; Jellinger, 1991; Thannickal et al., 2007; Zarow et al., 2003).”
BackgroundWakamatsu, K., Tabuchi, K., Ojika, M., Zucca, F. A., Zecca, L., & Ito, S. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13237 · Cited by 76
The pathology roadmap in Parkinson disease
Surmeier, D. J., & Sulzer, D. (2013) · Prion · doi:10.4161/pri.23582 · Cited by 74
Zucca, F. A., Capucciati, A., Bellei, C., Sarna, M., Sarna, T., Monzani, E., Casella, L., & Zecca, L. (2023) · IUBMB Life · doi:10.1002/iub.2654 · Cited by 69
“Both these regions are early targeted in Parkinson's disease (PD), while in Alzheimer's disease (AD) only LC is early damaged.(3,4) In AD and PD, the NM-containing neurons are preferentially lost compared to those without NM.”
BackgroundVulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Costello, H., Roiser, J. P., & Howard, R. (2023) · Psychological Medicine · doi:10.1017/s003329172200397x · Cited by 60
“Noradrenaline (Locus coeruleus (LC)) AD pathology occurs early in the LC, leading to severe loss of LC neurons (over 60%) (Grudzien et al., 2007; Zarow et al., 2003).”
Masilamoni, G. J., Groover, O., & Smith, Y. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.025 · Cited by 37
“Despite well-established evidence that brainstem NE neurons in the locus coeruleus and related brainstem cell groups degenerate in PD (Greenfield and Bosanquet, 1953; Ehringer and Hornykiewicz, 1960, 1998), sometimes to a greater extent than in SNc (Zarow et al., 2003), the importance of this degeneration in the devel…”
BackgroundInfluentialCapucciati, A., Zucca, F. A., Monzani, E., Zecca, L., Casella, L., & Hofer, T. (2021) · Antioxidants · doi:10.3390/antiox10060824 · Cited by 36
Fifel, K., Piggins, H., & Deboer, T. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.02.005 · Cited by 30
Mechanisms of Neuron Loss in Alzheimer’s Disease
Mukhin, V. N., Pavlov, K. I., & Klimenko, V. M. (2017) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-017-0427-x · Cited by 27
Midbrain fMRI: Applications, Limitations and Challenges
Düzel, E., Guitart-Masip, M., Maass, A., Hämmerer, D., Betts, M. J., Speck, O., Weiskopf, N., & Kanowski, M. (2015) · Biological Magnetic Resonance · doi:10.1007/978-1-4899-7591-1_20 · Cited by 16
Metadata
- Authors
- Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-03-01
- Volume
- 60
- Issue
- 3
- Pages
- 337
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2089289079
- Cited by
- 1,002
- References
- 37
- FWCI
- 19.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.